Yu Yong 4
4 · GENELUX Corp · Filed Jul 8, 2024
Insider Transaction Report
Form 4
GENELUX CorpGNLX
Yu Yong
VP, Clinical Trial Operations
Transactions
- Award
Common Stock
2024-02-19+3,661→ 6,161 total - Sale
Common Stock
2024-06-24$2.12/sh−6,849$14,520→ 10,869 total - Award
Common Stock
2024-03-14+11,557→ 17,718 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.
- [F2]Represents RSUs that are fully vested as of March 14, 2024.
- [F3]Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of RSUs.